Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

被引：5

作者：

Beltran, Himisha

Dowlati, Afshin

Jain, Prantesh

Johnson, Melissa Lynne

Sanborn, Rachel E.

Thompson, Jonathan Robert

Mamdani, Hirva

Schenk, Erin L.

Aggarwal, Rahul Raj

Sankar, Kamya

Gramza, Ann W.

Anand, Banmeet S.

Choudhury, Noura J.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Case Western Reserve Univ, Univ Hosp Siedman Canc Ctr, Cleveland, OH USA

[3] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Earle A Chiles Res Inst, Portland, OR USA

[6] Froedtert, Milwaukee, WI USA

[7] Med Coll Wisconsin, Workforce Hlth, Milwaukee, WI USA

[8] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[9] Univ Colorado Anschutz Med Campus, Aurora, CO USA

[10] Univ Calif San Francisco, San Francisco, CA USA

[11] Cedars Sinai Med Ctr, Los Angeles, CA USA

[12] Harpoon Therapeut Inc, South San Francisco, CA USA

[13] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

261-492-199-2823-7422-11198; 283-197-6219; 613-225-2577-2545; 283-183-138-226; 261-492-199-2823; 613-615-646-4685-2424; 613-225-2782; 6; 4; 3; 38092-34755; 38092-21757; 38092-21759; 5; 2; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：121 / 121

页数：1

共 36 条

[21] A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer
Lordick, F.
Buxo Orra, E.
Cervantes, A.
Dayyani, F.
Rocha-Lima, C.
Greil, R.
van Laarhoven, H.
Lorenzen, S.
Kischel, R.
Shitara, K.
Chao, J.
ANNALS OF ONCOLOGY, 2020, 31 : S114 - S114
[22] Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
Owonikoko, Taofeek K.
Champiat, Stephane
Johnson, Melissa Lynne
Govindan, Ramaswamy
Izumi, Hiroki
Lai, W. Victoria Victoria
Borghaei, Hossein
Boyer, Michael J.
Boosman, Rene J.
Hummel, Horst-Dieter
Blackhall, Fiona Helen
Reguart, Noemi
Dowlati, Afshin
Zhang, Yiran
Mukherjee, Sujoy
Minocha, Mukul
Zhou, Yanchen
Shetty, Aditya
Sadraei, Nooshin Hashemi
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Ben Tran
Horvath, Lisa
Rettig, Matthew
Fizazi, Karim
Lolkema, Martijn P.
Dorff, Tanya B.
Greil, Richard
Machiels, Jean-Pascal H.
Autio, Karen A.
Rottey, Sylvie
Adra, Nabil
Garje, Rohan
Roncolato, Felicia
Tagawa, Scott T.
Shariat, Shahrokh F.
Salvati, Mark
Poon, Shirley
Kouros-Mehr, Hosein
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
Paz-Ares, L.
Owonikoko, T. K.
Johnson, M.
Govindan, R.
Izumi, H.
Lai, V.
Borghaei, H.
Boyer, M.
Boosman, R. J.
Hummel, H-D.
Blackhall, F.
Dowlati, A.
Zhang, Y.
Mukherjee, S.
Sable, B.
Pati, A.
Shetty, A.
Sadraei, N. Hashemi
Champiat, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S720 - S721
[25] DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)
Gadgeel, S. M.
Al-Mondhiry, J.
Ahn, M-J.
Kim, S-W.
Paz-Ares, L.
Prenen, H.
Boyer, M.
Bustamante Alvarez, J. G.
Solomon, B.
Huang, S.
Minocha, M.
Kistler, M.
Sadraei, N. Hashemi
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1255 - S1255
[26] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)
Tran, Ben
Horvath, Lisa
Dorff, Tanya B.
Greil, Richard
Machiels, Jean-Pascal H.
Roncolato, Felicia
Autio, Karen A.
Rettig, Matthew
Fizazi, Karim
Lolkema, Martijn P.
Fermin, Anthony C.
Salvati, Mark
Kouros-Mehr, Hosein
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[27] Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
Ramalingam, S. S.
Ahn, M-J.
Akamatsu, H.
Blackhall, F.
Borghaei, H.
Hummel, H-D.
Johnson, M.
Reck, M.
Zhang, Y.
Jandial, D.
Cheng, S.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2022, 33 : S103 - S104
[28] A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Tran, B.
Kouros-Mehr, H.
Fermin, A.
Horvath, L.
Roncolato, F.
Rettig, M.
Dorff, T.
Tagawa, S. T.
Subudhi, S. K.
Antonarakis, E. S.
Armstrong, A. J.
Petrylak, D. P.
Fizazi, K.
Salvati, M. E.
Scher, H. I.
ANNALS OF ONCOLOGY, 2019, 30 : 353 - 353
[29] Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
Tran, B.
Horvath, L.
Dorff, T.
Rettig, M.
Lolkema, M. P.
Machiels, J-P.
Rottey, S.
Autio, K.
Greil, R.
Adra, N.
Lemech, C.
Minocha, M.
Cheng, F-C.
Kouros-Mehr, H.
Fizazi, K.
ANNALS OF ONCOLOGY, 2020, 31 : S507 - S507
[30] Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma
Wang, Q.
Chai, X.
Lin, R.
Zheng, L.
Cao, D.
Qu, X.
Liu, L.
Wu, L.
Mou, H.
Xu, Q.
Shi, J.
ANNALS OF ONCOLOGY, 2024, 35 : S532 - S533

← 1 2 3 4 →